Intravitreal Anti-VEGF and Systemic Outcomes After Cardiovascular Events This cohort study evaluated if pericardiovascular event treatment is associated with mortality or major sequelae in patients receiving intravitreal anti–vascular endothelial growth factor (anti-VEGF) ...

Terapia anti-VEGF cerca del evento CV no se asocia con una mayor mortalidad o morbilidad, independientemente del anti-VEGF, por lo que es seguro continuar con la terapia intravítrea sin modificarla durante el evento CV #AntiVEGF #CVevent jamanetwork.com/journals/jam...